Published in PLoS Pathog on August 21, 2009
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Immunology and the elusive AIDS vaccine. Nature (2010) 2.26
Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem (2010) 2.23
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS (2011) 2.00
Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics (2011) 1.71
An integrated overview of HIV-1 latency. Cell (2013) 1.68
The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS (2011) 1.67
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol (2011) 1.61
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Novel genetic locus implicated for HIV-1 acquisition with putative regulatory links to HIV replication and infectivity: a genome-wide association study. PLoS One (2015) 1.46
Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology (2014) 1.45
Nuclear landscape of HIV-1 infection and integration. Nat Rev Microbiol (2016) 1.41
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Snapshots: chromatin control of viral infection. Virology (2013) 1.39
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol (2011) 1.34
Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog (2011) 1.31
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology (2011) 1.31
Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods (2010) 1.29
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One (2012) 1.23
Combined approaches for HIV cure. Curr Opin HIV AIDS (2013) 1.23
Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res (2011) 1.23
HIV infection and HERV expression: a review. Retrovirology (2012) 1.19
HIV latency: experimental systems and molecular models. FEMS Microbiol Rev (2012) 1.19
Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol (2012) 1.15
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio (2015) 1.13
T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol (2011) 1.12
Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol (2011) 1.10
Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes. PLoS Pathog (2013) 1.09
Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol (2012) 1.07
Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther (2012) 1.05
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS (2014) 1.05
Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. Mol Cell Biol (2014) 1.03
In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. Methods (2010) 1.02
Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses (2011) 0.99
Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumtol (2011) 0.98
Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics (2015) 0.98
Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J (2010) 0.98
The viral protein Tat can inhibit the establishment of HIV-1 latency. J Virol (2012) 0.97
Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral origin. Nucleic Acids Res (2011) 0.96
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Retroviral DNA methylation and epigenetic repression are mediated by the antiviral host protein Daxx. J Virol (2012) 0.95
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS (2011) 0.95
Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virol (2010) 0.93
Viral-host interactions that control HIV-1 transcriptional elongation. Chem Rev (2013) 0.93
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother (2014) 0.92
HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol (2012) 0.92
LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res (2011) 0.90
Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy. Mol Syst Biol (2010) 0.89
Epigenetic regulation of HIV-1 latency in astrocytes. J Virol (2013) 0.89
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Whole genome methylation array reveals the down-regulation of IGFBP6 and SATB2 by HIV-1. Sci Rep (2015) 0.89
HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad (2015) 0.87
Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol (2011) 0.87
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells. J Virol (2013) 0.86
Chromatin accessibility at the HIV LTR promoter sets a threshold for NF-κB mediated viral gene expression. Integr Biol (Camb) (2012) 0.86
Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications. Virology (2014) 0.85
Transcriptional provirus silencing as a crosstalk of de novo DNA methylation and epigenomic features at the integration site. Nucleic Acids Res (2012) 0.85
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter. Retrovirology (2011) 0.84
Relationship between LTR methylation and gag expression of HIV-1 in human spermatozoa and sperm-derived embryos. PLoS One (2013) 0.84
Epigenetic heterogeneity in HIV-1 latency establishment. Sci Rep (2015) 0.83
Fine mapping genetic determinants of the highly variably expressed MHC gene ZFP57. Eur J Hum Genet (2013) 0.82
The immunological synapse: the gateway to the HIV reservoir. Immunol Rev (2013) 0.82
Therapy for persistent HIV. Trends Pharmacol Sci (2010) 0.82
Proliferation of latently infected CD4(+) T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. J Exp Med (2017) 0.81
Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy. Cell Mol Bioeng (2014) 0.81
Feline immunodeficiency virus latency. Retrovirology (2013) 0.81
Poly(ADP-ribose) polymerase 1 promotes transcriptional repression of integrated retroviruses. J Virol (2012) 0.81
(Some) cellular mechanisms influencing the transcription of human endogenous retrovirus, HERV-Fc1. PLoS One (2013) 0.81
The BAF complex and HIV latency. Transcription (2012) 0.81
Epigenetics, drugs of abuse, and the retroviral promoter. J Neuroimmune Pharmacol (2013) 0.80
Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol Med (2015) 0.80
Nuclear positional control of HIV transcription in 4D. Nucleus (2011) 0.80
Cancer therapies in HIV cure research. Curr Opin HIV AIDS (2017) 0.79
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. J Infect Dis (2017) 0.79
Epigenetic alterations in the brain associated with HIV-1 infection and methamphetamine dependence. PLoS One (2014) 0.79
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79
Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. Virology (2013) 0.78
Role of DNA methylation in expression and transmission of porcine endogenous retroviruses. J Virol (2013) 0.78
Ectopic DNMT3L triggers assembly of a repressive complex for retroviral silencing in somatic cells. J Virol (2014) 0.78
The effects of cocaine on HIV transcription. J Neurovirol (2015) 0.78
Interaction between endogenous bacterial flora and latent HIV infection. Clin Vaccine Immunol (2013) 0.77
HIV eradication: combinatorial approaches to activate latent viruses. Viruses (2014) 0.77
Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clin Epigenetics (2016) 0.77
Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77
Sulfonation pathway inhibitors block reactivation of latent HIV-1. Virology (2014) 0.77
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 11.12
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
HIV disease: fallout from a mucosal catastrophe? Nat Immunol (2006) 5.08
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A (1997) 4.71
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J (2001) 3.80
DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning. Proc Natl Acad Sci U S A (1981) 3.70
Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol (2005) 3.51
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 3.10
HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J (1999) 3.10
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood (2008) 3.05
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol (2002) 2.64
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J (2003) 2.43
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest (2005) 2.41
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell (1998) 2.23
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.00
Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J (1990) 1.98
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis (2000) 1.96
DNA-methylation analysis by the bisulfite-assisted genomic sequencing method. Methods Mol Biol (2002) 1.91
Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J (2006) 1.87
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today (2005) 1.80
Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J (2000) 1.78
The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem (2006) 1.77
5'-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol (2002) 1.77
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol (2005) 1.72
Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol (2006) 1.68
Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol (2004) 1.64
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology (2005) 1.55
Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol (2001) 1.48
5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology (2006) 1.45
Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol (2003) 1.40
Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci U S A (1998) 1.37
CpG methylation suppresses transcriptional activity of human syncytin-1 in non-placental tissues. Exp Cell Res (2006) 1.34
Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol (2004) 1.32
Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol (2002) 1.29
Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci U S A (2009) 1.19
Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol (2003) 1.15
CpG island protects Rous sarcoma virus-derived vectors integrated into nonpermissive cells from DNA methylation and transcriptional suppression. Proc Natl Acad Sci U S A (2001) 1.11
Transcription of HIV1 is inhibited by DNA methylation. Biochem Biophys Res Commun (1990) 1.05
Extrachromosomal human immunodeficiency virus type 1 sequences are methylated in latently infected U937 cells. Virology (1992) 0.93
Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells. Virology (1999) 0.91
R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors. J Virol (2006) 0.86
Truncated forms of human and simian immunodeficiency virus in infected individuals and rhesus macaques are unique or rare quasispecies. Virology (2003) 0.81
The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 8.34
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 7.97
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature (2010) 6.48
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A (2006) 5.96
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol (2002) 5.37
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab (2010) 4.97
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Conserved metabolic regulatory functions of sirtuins. Cell Metab (2008) 3.86
Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science (2012) 3.52
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol (2004) 3.00
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci U S A (2007) 2.97
The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics (2011) 2.83
SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab (2010) 2.77
IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology (2015) 2.76
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics (2012) 2.66
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood (2012) 2.57
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol (2011) 2.49
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem (2007) 2.37
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol (2005) 2.24
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell (2002) 2.20
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol (2008) 2.12
HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 2.10
Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J (2002) 2.06
Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol (2013) 2.04
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 2.03
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc Natl Acad Sci U S A (2013) 2.01
Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol (2004) 1.92
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
The nexus of chromatin regulation and intermediary metabolism. Nature (2013) 1.87
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol (2011) 1.81
Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A (2008) 1.80
PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol (2011) 1.79
Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem (2004) 1.79
The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem (2006) 1.77
The Cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell Host Microbe (2010) 1.76
miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY) (2010) 1.76
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood (2008) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med (2004) 1.71
SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab (2013) 1.70
Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J (2005) 1.70
The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J Neurosci (2009) 1.69
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 1.68
Mitochondrial sirtuins. Biochim Biophys Acta (2010) 1.67
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem (2003) 1.66
The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood (2013) 1.65
Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol (2004) 1.63
HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int (2014) 1.62
Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J Biol Chem (2002) 1.62
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int (2008) 1.62
Interstitial pneumonia recurrence during chronic hepatitis C treatment. Am J Gastroenterol (2005) 1.60
Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem (2012) 1.58
Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J Biol Chem (2007) 1.55
Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab (2012) 1.52
Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability. Hepatology (2010) 1.52
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol (2010) 1.51
Immunosenescence and HIV. Curr Opin Immunol (2012) 1.51
Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One (2007) 1.50
Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J (2002) 1.49
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
MicroRNAs of the miR-17∼92 family are critical regulators of T(FH) differentiation. Nat Immunol (2013) 1.48
Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry A (2014) 1.48
Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol (2007) 1.48
Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem (2011) 1.43
Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol Cell (2003) 1.42
Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice. J Proteome Res (2012) 1.41
Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn (2011) 1.41
Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat Chem Biol (2012) 1.39
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS (2012) 1.38
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Dynamic recruitment of the adaptor protein LAT: LAT exists in two distinct intracellular pools and controls its own recruitment. J Cell Sci (2004) 1.37
Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials (2002) 1.37
A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci (2008) 1.36
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol (2007) 1.35
Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer (2010) 1.34
Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett (2007) 1.34